Voyager Therapeutics, Inc.VYGRNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank49
3Y CAGR-53.1%
5Y CAGR-25.7%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-53.1%/yr
vs -7.6%/yr prior
5Y CAGR
-25.7%/yr
Recent deceleration
Acceleration
-45.5pp
Decelerating
Percentile
P49
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 2.53% |
| Q3 2025 | 6.65% |
| Q2 2025 | 12.23% |
| Q1 2025 | -160.82% |
| Q4 2024 | 48.05% |
| Q3 2024 | 11.44% |
| Q2 2024 | -153.74% |
| Q1 2024 | 347.34% |
| Q4 2023 | -12.87% |
| Q3 2023 | -2421.08% |
| Q2 2023 | -100.68% |
| Q1 2023 | 1109.19% |
| Q4 2022 | 24.45% |
| Q3 2022 | 12.33% |
| Q2 2022 | -153.70% |
| Q1 2022 | 207.51% |
| Q4 2021 | 154.06% |
| Q3 2021 | 8.84% |
| Q2 2021 | -6.68% |
| Q1 2021 | 3.11% |
| Q4 2020 | 11.17% |
| Q3 2020 | -16.69% |
| Q2 2020 | 26.38% |
| Q1 2020 | -23.28% |
| Q4 2019 | -8.25% |
| Q3 2019 | 31.62% |
| Q2 2019 | -125.21% |
| Q1 2019 | 614.05% |
| Q4 2018 | -37.97% |
| Q3 2018 | 21.58% |
| Q2 2018 | -146.29% |
| Q1 2018 | 427.69% |
| Q4 2017 | 6.63% |
| Q3 2017 | 2.74% |
| Q2 2017 | -14.28% |
| Q1 2017 | -9.18% |
| Q4 2016 | -28.49% |
| Q3 2016 | -4.89% |
| Q2 2016 | -2.39% |
| Q1 2016 | 0.73% |